在高血压β-阻断剂的当前位置:指南和临床实践
Felix Mahfoud1, Jiguang Wang2, Saumitra Ray3
1Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
Current medical research and opinion
|April 10, 2024
概括
欧洲高血压学会最新的指导方针现在包括β阻塞剂用于初始高血压治疗,强调降低血压而不是特定药物类别. 建议进行组合治疗,特别是使用通道阻断剂,以获得最佳的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 高血压管理 高血压管理
背景情况:
- 降低血压显著改善了临床结果,这是众多研究证实的.
- 欧洲高血压学会 (ESH) 2023年指南更新了β抑制剂在高血压管理中的作用.
- 之前的ESH指导方针 (2018年) 主要为患有特定心血管并发症的患者推β-阻断剂.
研究的目的:
- 根据2023年ESH指南,根据高血压管理中使用β-阻断剂的最新建议进行总结.
- 为了突出指导方针哲学转向优先考虑降低血压大小的转变.
- 为了强调将β阻塞剂与其他抗高血压药物,特别是二皮里丁通道阻塞剂相结合的合理性.
主要方法:
- 欧洲高血压学会 (ESH) 2023年高血压管理指南的审查.
- 分析证据支持降低血压在预防心血管不良后果方面的有效性.
- 审查关于启动和联合治疗抗高血压药物的最新建议,包括β-阻断剂.
主要成果:
- 2023年ESH指导方针包括β-阻断剂作为开始抗高血压药物治疗的初级类.
- 该指南强调,降低血压的程度是降低心血管风险的关键决定因素.
- 现在,由于同情性过度活跃,建议对患有高静止心率 (>80bpm) 的患者使用β-阻断剂.
- 对大多数高血压患者来说,建议使用组合疗法,理想情况下是单一的药片.
- 将β阻塞剂与二皮里丁通道阻塞剂相结合是一种合理的方法,可以降低中央和外周血压.
结论:
- 更新的ESH指南反映了更广泛的高血压治疗方法,更广泛地纳入β阻塞剂.
- 实现显著的血压降低对于减轻心血管风险至关重要.
- 组合疗法,特别是β-阻断剂和二皮里丁通道阻断剂,在管理高血压和降低相关发病率和死亡率方面具有战略优势.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
794
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
794
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
593
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
593
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
Antihypertensive Drugs: Types of β-Blockers
671
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
671
Antihypertensive Drugs: Action of β1 Blockers
441
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
441


